HN2011003139A - Antagonistas de trayectoria de erizo de ftalazina disustituida - Google Patents
Antagonistas de trayectoria de erizo de ftalazina disustituidaInfo
- Publication number
- HN2011003139A HN2011003139A HN2011003139A HN2011003139A HN2011003139A HN 2011003139 A HN2011003139 A HN 2011003139A HN 2011003139 A HN2011003139 A HN 2011003139A HN 2011003139 A HN2011003139 A HN 2011003139A HN 2011003139 A HN2011003139 A HN 2011003139A
- Authority
- HN
- Honduras
- Prior art keywords
- ftalazina
- disttituted
- antegonis
- hize
- history
- Prior art date
Links
- 241000027355 Ferocactus setispinus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HN2011003139A true HN2011003139A (es) | 2013-07-29 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HN2011003139A HN2011003139A (es) | 2009-06-19 | 2011-11-29 | Antagonistas de trayectoria de erizo de ftalazina disustituida |
Country Status (35)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2723042A1 (en) * | 2008-04-29 | 2009-11-05 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| DK2364185T3 (da) * | 2008-11-03 | 2013-06-03 | Lilly Co Eli | Disubstituerede phthalazin-hedgehog-pathway-antagonister |
| CN102216292B (zh) * | 2008-11-17 | 2014-08-13 | 伊莱利利公司 | 四取代的哒嗪hedgehog途径拮抗剂 |
| AU2009314349B2 (en) | 2008-11-17 | 2013-04-18 | Eli Lilly And Company | Tetrasubstituted pyridazine hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| AU2012232670A1 (en) | 2011-03-23 | 2013-09-12 | Ariel-University Research And Development Company Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| CA2988289C (en) | 2015-06-04 | 2023-12-05 | PellePharm, Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
| EP3303289A4 (en) * | 2015-06-05 | 2018-11-14 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| JP7158023B2 (ja) | 2016-03-15 | 2022-10-21 | オリソン ヘノミクス エセ． アー． | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) * | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| WO2018211007A1 (en) | 2017-05-18 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| US20230301950A1 (en) | 2020-06-26 | 2023-09-28 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| AU2021360767A1 (en) * | 2020-10-13 | 2023-04-27 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (cg-RX-API-DMAC7.html) * | 1977-06-03 | 1981-03-07 | Pfizer | |
| ZA97288B (en) | 1996-01-15 | 1998-07-14 | Janssen Pharmaceutica Nv | Angiogenesis inhibiting pyridazinamines |
| JP5067986B2 (ja) | 1998-04-09 | 2012-11-07 | ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン | ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用 |
| CA2376210A1 (en) | 1999-06-08 | 2000-12-14 | Lorantis Limited | Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| MXPA04000803A (es) * | 2001-07-27 | 2004-05-21 | Curis Inc | Mediadores de rutas de senalizacion de hedgehog, composiciones y usos relacionados a los mismos. |
| JP2005529876A (ja) * | 2002-04-22 | 2005-10-06 | ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | Ｈｅｄｇｅｈｏｇシグナル伝達経路の調節因子、それに関連する組成物および使用 |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| CA2564996A1 (en) | 2004-05-08 | 2006-01-12 | Taeyoung Yoon | 3-aryl-5,6-disubstituted pyridazines |
| KR101225018B1 (ko) | 2004-09-02 | 2013-01-23 | 쿠리스 인코퍼레이션 | 헤지호그 신호전달에 대한 피리딜 억제제 |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| JP5550352B2 (ja) * | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| EP2170866B1 (en) * | 2007-06-25 | 2014-08-13 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| CA2697682A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling |
| JP5620821B2 (ja) * | 2007-12-13 | 2014-11-05 | シエナ ビオテク ソシエタ ペル アチオニＳｉｅｎａ Ｂｉｏｔｅｃｈ Ｓ．Ｐ．Ａ． | ヘッジホッグ経路拮抗薬およびその治療用途 |
| CA2723042A1 (en) * | 2008-04-29 | 2009-11-05 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| EP2321298B1 (en) * | 2008-08-04 | 2013-10-02 | Amgen Inc. | Aurora kinase modulators and methods of use |
| DK2364185T3 (da) | 2008-11-03 | 2013-06-03 | Lilly Co Eli | Disubstituerede phthalazin-hedgehog-pathway-antagonister |
| CN102216292B (zh) | 2008-11-17 | 2014-08-13 | 伊莱利利公司 | 四取代的哒嗪hedgehog途径拮抗剂 |
| AU2009314349B2 (en) | 2008-11-17 | 2013-04-18 | Eli Lilly And Company | Tetrasubstituted pyridazine hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HN2011003139A (es) | Antagonistas de trayectoria de erizo de ftalazina disustituida | |
| CR11741A (es) | Antagonistas de la trayectoria hedgehog de ftalazina disustituida | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| CU20140025A7 (es) | Pirimidinas anilladas sustituidas | |
| BR112012010923A2 (pt) | cepa de bifidobactéria | |
| UY31484A1 (es) | Piperidinas heteroaril-sustituidas | |
| SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| HN2010002518A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
| HN2011002809A (es) | Compuestos de vinil indazolilo | |
| CO7020878A2 (es) | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma | |
| HN2007015177A (es) | Derivados de triazolopirazina | |
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| UY31136A1 (es) | Oxazolidinonas sustituidas y su uso | |
| HN2012000973A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| HRP20160551T8 (hr) | Kombinirana terapija s pripravcima nanočestica taksana i hedgehog inhibitora | |
| IL234101A0 (en) | New therapeutic approaches for treating parkinson's disease | |
| ECSP11011021A (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| CO6801718A2 (es) | Composición terapéutica para el tratamiento de glioblastoma | |
| CR11168A (es) | OXAZOLIDINON-5-lL-METIL)-2-TIOFEN-CARBOXAMIDAS SUSTITUIDAS Y SU USO EN EL CAMPO DE LA COAGULACION SANGUINEA | |
| ECSP11011483A (es) | Piperidinas sustituidas | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| HN2011003102A (es) | Piperidinas sustituidas | |
| BR112013007039A2 (pt) | "composição de tratamento pessoal" | |
| IT1402712B1 (it) | Unita' per l'esecuzione di trattamenti estetici, cosmetici e terapeutici. | |
| HRP20151393T8 (hr) | UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE |